Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 10:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–23 of 23 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Mild to Moderately Active Ulcerative Colitis Clear all
Completed Phase 3 Interventional Results available

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis

NCT00713310
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol 400 mg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
5 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2012 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Phase 1Phase 2 Interventional

Safety and Pharmacokinetics Study of HE3286 in Patients With Active, Mild-to-Moderate Ulcerative Colitis

NCT00628433
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Placebo, HE3286
Drug
Lead sponsor
Harbor Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
10
States / cities
Tucson, Arizona • Anaheim, California • Fresno, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2011 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

Mesalamine 4 g Sachet for the Induction of Remission in Active, Mild to Moderate Ulcerative Colitis (UC)

NCT02522767
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine, Placebo
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
18
States / cities
Little Rock, Arkansas • Murrieta, California • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Phase 3 Interventional

Balsalazide Disodium vs. Mesalamine in Mildly to Moderately Active Ulcerative Colitis

NCT00408174
View directory record Official record
Conditions
Inflammatory Bowel Disease, Ulcerative Colitis
Interventions
Balsalazide disodium
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
88
States / cities
Tempe, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 74 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 22, 2026, 10:23 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of MAX-002 Suppository Versus Placebo and Active Medicine in Mild to Moderate Ulcerative Proctitis

NCT01016262
View directory record Official record
Conditions
Proctitis, Ulcerative
Interventions
MAX-002, Placebo, Canasa®
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
22
States / cities
Birmingham, Alabama • Dothan, Alabama • Tucson, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Jul 22, 2026, 10:23 PM EDT
Terminated Phase 2 Interventional Results available

A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)

NCT04556383
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
GB004, Placebo
Drug
Lead sponsor
GB004, Inc.
Industry
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
13
States / cities
Encinitas, California • Lancaster, California • Baton Rouge, Louisiana + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2023 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

New Tablet Formulation and Dosing Regimen of Balsalazide Disodium in Mildly to Moderately Active Ulcerative Colitis

NCT00269438
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
5 ASA, enemas, suppositories, corticosteroids
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 57 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Phase 2 Interventional Results available

Pilot Study of Green Tea Extract (Polyphenon E®)in Ulcerative Colitis

NCT00718094
View directory record Official record
Conditions
Mild to Moderately Active Ulcerative Colitis
Interventions
Polyphenon E®, Placebo Oral Tablet
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Dec 13, 2017 · Synced Jul 22, 2026, 10:23 PM EDT
Terminated Phase 3 Interventional Results available

A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis

NCT01805791
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
HMPL-004 1800 mg/day, Placebo, HMPL-004 2400 mg/day
Drug
Lead sponsor
Hutchison Medipharma Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Agawam, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 1, 2020 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

NCT01008423
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
62
States / cities
Dothan, Alabama • Mesa, Arizona • Tucson, Arizona + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

ISIS 2302-CS27, A 6-Week, Placebo-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis.

NCT00063830
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Alicaforsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day (ASCEND I)

NCT00577473
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
mesalamine
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 65 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
44
States / cities
Birmingham, Alabama • Anaheim, California • Sacramento, California + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Jul 22, 2026, 10:23 PM EDT
Terminated Phase 1 Interventional

ABI-M201 in Adult Subjects With Mildly-to-Moderately Active Ulcerative Colitis

NCT03923478
View directory record Official record
Conditions
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate
Interventions
ABI-M201, Placebo
Drug
Lead sponsor
Assembly Biosciences
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
10
States / cities
Oakland, California • San Carlos, California • Decatur, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Budesonide Foam for Participants With Active Mild to Moderate Ulcerative Proctitis or Proctosigmoiditis

NCT01008410
View directory record Official record
Conditions
Proctitis, Proctosigmoiditis
Interventions
Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
63
States / cities
Birmingham, Alabama • Huntsville, Alabama • Jonesboro, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Jul 22, 2026, 10:23 PM EDT
Recruiting Phase 4 Interventional

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Extended-release Tablets in Pediatric Subjects Aged 5 to 17 Years With Active, Mild to Moderate Ulcerative Colitis

NCT04314375
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Low Dose Budesonide, High Dose Budesonide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
5 Years to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Garden Grove, California • Indianapolis, Indiana • The Bronx, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Phase 4 Interventional

Use of a Novel Diet (UC DIET) for Treatment of Mild to Moderate Active Pediatric Ulcerative Colitis

NCT02345733
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
Ulcerative Colitis Diet, Antibiotic cocktail
Other · Drug
Lead sponsor
Prof. Arie Levine
Government
Eligibility
8 Years to 19 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2022 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

TD-3504 SAD in Healthy Subjects and Subjects With Ulcerative Colitis (UC)

NCT03103412
View directory record Official record
Conditions
Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
Interventions
TD-3504, 15N2-tofacitinib, Placebo
Drug
Lead sponsor
Theravance Biopharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2021 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Phase 3 Interventional Results available

Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)

NCT01532648
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Budesonide MMX®, Placebo, 5-ASA
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
39
States / cities
Anaheim, California • Lakewood, California • San Diego, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Not applicable Interventional

Microbiota-targeted Diet for Pediatric UC

NCT02922881
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Ulcerative Colitis Diet (UCD)
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
8 Years to 19 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 21, 2021 · Synced Jul 22, 2026, 10:23 PM EDT
Recruiting Phase 1 Interventional

R-3750 in Patients With Mild to Moderate Ulcerative Colitis

NCT05666960
View directory record Official record
Conditions
Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic, Ulcerative Colitis
Interventions
R-3750
Drug
Lead sponsor
Rise Therapeutics LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Valencia, California • Miami, Florida • Plantation, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 22, 2026, 10:23 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess Efficacy and Safety of SER-287 in Adults With Active Mild-to-Moderate Ulcerative Colitis

NCT03759041
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Vancomycin Pre-Treatment, Placebo for Vancomycin Pre-Treatment, SER-287, Placebo for SER-287
Drug
Lead sponsor
Seres Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
81
States / cities
Phoenix, Arizona • North Little Rock, Arkansas • La Jolla, California + 70 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2022 · Synced Jul 22, 2026, 10:23 PM EDT
Recruiting Phase 2 Interventional

Confirmatory Clinical Study in Active Ulcerative Colitis

NCT07296315
View directory record Official record
Conditions
Colitis, Ulcerative
Interventions
Low-dose MH002, High-dose MH002, Placebo
Drug
Lead sponsor
MRM Health NV
Industry
Eligibility
16 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
6
States / cities
Miami, Florida • Orlando, Florida • Palmetto Bay, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Jul 22, 2026, 10:23 PM EDT
Completed Phase 2 Interventional

ISIS 2302-CS22, A 6-Week, Active-Controlled Clinical Study to Evaluate the Effectiveness of Alicaforsen (ISIS 2302) in Patients With Mild to Moderate Active Ulcerative Colitis

NCT00063414
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Alicaforsen
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 4, 2022 · Synced Jul 22, 2026, 10:23 PM EDT